臺灣博碩士論文加值系統

研究目的︰原發子宮頸腺癌與原發子宮內膜腺癌因病變解剖位置靠近，有時在臨床上與病理上，都不易區分；尤其發生上下延伸侵犯時，更難以區分何者為原發部位。二者基本生物特性差異極大，臨床上這兩個地方癌症的治療方式完全不同，而且一直缺乏可靠的區分方式。當發生腺癌來源無法判斷時，在婦科病理學中，免疫組織染色法可提供輔助診斷。本研究包括三部份﹕(1)找出最適當且簡單的計分法可以應用於p16INK4a免疫組織染色，在臨床上輔助鑑別診斷子宮頸腺癌及子宮內膜腺癌。(2)除p16INK4a外，再針對其他常用於鑑別診斷子宮頸腺癌及子宮內膜腺癌的四種組織免疫標誌（包括ER, PR, Vim, CEA），進行驗證﹔(3)期望能整合數種潛在有用的免疫組織標誌，開發出最妥適生物標誌診斷套組，以進行子宮頸腺癌與子宮內膜腺癌鑑別診斷。
材料與方法︰本研究樣本來自早年就已經去連結檢體，包括14例子宮頸腺癌與21例子宮內膜腺癌，製成石蠟包埋之組織蠟塊，做成微陣列排序的組織晶片。以五種生物標誌(包括ER, PR, Vim, CEA, p16INK4a)抗體，採用avidin-biotin complex 技術，進行免疫組織染色。採用semiquantative計分法，考量染色強度及區城面積做評分的依據。

結果︰我們的結果顯示(1) 在p16INK4a的四個計分方法中，包括「單獨胞核評估計分法」、「單獨胞質評估計分法」、「胞核與胞質分數之平均計分法」、「胞核與胞質之單獨計分較高者計分法」等四者；其中之p16INK4a免疫組織呈色的「單獨胞質評估計分法」，對區分子宮頸腺癌及子宮內膜腺癌並不具統計學上意義，而其他三種計分法則有明顯差異。(2) 除p16INK4a以外，其餘四種生物標誌（ER, PR, Vim, CEA），在子宮頸腺癌及子宮內膜腺癌的免疫組織呈色，也都出現有意義的顯著差異。(3)經比較各種組合，我們證實︰以二合一生物標誌 (Vim，CEA) 組合，在鑑別原發性子宮頸腺癌及子宮內膜腺癌的診斷中，呈現最佳的整體準確度(overall accuracy)，達0.783 (0.648, 0.917)。

結論: 我們的研究證實︰(1) 使用p16INK4a生物標誌時，以較為簡單方便的單獨胞核評估計分法，不需考慮細胞質呈色的結果，就足以區分原發性子宮頸腺癌與原發性子宮內膜腺癌。(2)另外四種個別生物標誌（ER, PR, Vim, CEA），對區分原發性子宮頸腺癌與原發性子宮內膜腺癌，亦有幫助。(3) 五合一、四合一、三合一、及二合一的各種生物標誌組合(panels)，都可以用於鑑別診斷原發性子宮頸腺癌與原發性子宮內膜腺癌， 但二合一生物標誌組合中之 Vim/CEA panel， 應該是最經濟有效的組合了。

Objective: The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor’s site of origin, because they have differing biological behaviors. Although careful morphologic examination usually results in a confident diagnosis, difficulties may also arise in the pathological examination of a large surgically resected specimen for a tumor that involves both the lower uterine segment and upper endocervix. When there is doubt and indistinguishable primaries, immunohistochemistry (IHC) may assist. The purposes of this study are: (1) to define a sufficient, simple and useful scoring mean of p16INK4a in distinguishing between ECA and EMA (2) to compare the individual expression status of five immunomarkers (ER, PR, Vim, CEA and p16INK4a). (3) to determine the most favorable panel in distinguishing between ECA and EMA.

Methods and materials: A tissue microarray (TMA) was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. TMA sections were immunostained with five antibodies, by avidine-biotin complex (ABC) method for antigen visualization. The staining intensity and area extent of the immunohistochemical (IHC) reactions were appraised by using the semi-quantitative scoring system.

Result: (1) Method Cytoplasm for p16INK4a IHC was not a statistically significant method to distinguish between ECA and EMA. However the other three methods for p16INK4a IHC, Method Nucleus, Method Mean of Cytoplasm plus Nucleus, and Method Dominant Cytoplasm or Nucleus, resulted in significant frequency differences between ECA and EMA. The overall accuracy rate of Method Mean of Cytoplasm plus Nucleus was 80 %, the highest among the four scoring methods. (2) The expressions of five respective markers (ER, PR, Vim, CEA and p16INK4a) showed significant frequency differences between ECA and EMA. (3) The 2-markers (Vim, CEA) panel exhibited the most efficiency in the diagnostic distinction between primary ECA and EMA.

Conclusions: Method Nucleus, based on independent of cytoplasmic stains, can conveniently and effectively distinguish between ECA and EMA. The 2- markers (Vim, CEA) panel would be sufficient in making a diagnostic distinction between primary ECA and EMA

中文摘要………………......…….......................…………..................1

英文摘要………………..……….…………..........................................4

第一章　緒論

第一節 文獻回顧………………………………………………………...6

第二節 研究目的…………………………………………………….….16

第二章　研究材料與方法....................................................18

第三章　研究結果……………………….…………….........……………..24

第四章　討論......................................................................30

第五章　結論…………………………………………………………………….37

表格.………………………………………………………………………..………..38

圖………………………………………….…..........................................51

參考文獻…………………………………...........................................57

已出版論文…………………………….............................................74

1.行政院衛生署國民健康局資訊網
2.Luran JR, Bidus MA, Elkas JC: Uterine cancer, cervical and vaginal cancer. In Novak''s Gynecology. 14th edition. Edited by Berek RS. Lippincott Williams & Wilkins (LWW), Philadelphia; 2007:1343-1402.
3.Chen YY, You SL, Chen CA, Shih LY, Koong SL, Chao KY, Hsiao ML, Hsieh CY, Chen CJ; Taiwan Cervical Cancer Screening Task Force. Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. Br J Cancer. 2009 Jul 7;101(1):174-177.
4.Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995 Oct;59(1):38-44.
5.Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R, Terakawa N. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol. 2000 Aug;26(5):464-467.
6.Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhorst TJ. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004 Jan;92(1):262-267.
7.Greenspan DL, Cardillo M, Davey DD, Heller DS, Moriarty AT. Endometrial cells in cervical cytology: review of cytological features and clinical assessment. J Low Genit Tract Dis. 2006 Apr;10(2):111-122.
8.Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of the cervix. Curr Treat Options Oncol. 2004 Apr;5(2):119-127.
9.Zaino RJ. The fruits of our labors: distinguishing endometrial from endocervical adenocarcinoma. Int J Gynecol Pathol. 2002 Jan;21(1):1-3.
10.Lotze MT, Gray J. A life in passing: Jonathan Gray. J Transl Med. 2007 Oct 30;5:54.
11.Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002 Jan;21(1):4-10.
12.McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002 Jan;21(1):11-15.
13.Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003 Mar;442(3):271-277.
14.Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer. 2001 Feb 25;93(1):8-15.
15.Sellors JW, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: A beginners'' manual. Lyon, France: International Agency for Research on Cancer, 2003.
16.Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999 Oct;75(1):55-61.
17.zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78.
18.zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002 May;2(5):342-50.
19.Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301-328.
20.zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol. 1994;48:427-447.
21.Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, Meijer CL, Snijders PJ, Chatis P, Broker TR, Moen PT Jr, Chow LT. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol. 2004 Oct;78(20):11172-11186.
22.Ishikawa M, Fujii T, Masumoto N, Saito M, Mukai M, Nindl I, Ridder R, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol. 2003 Oct;22(4):378-385.
23.Münger K, Howley PM. Human papillomavirus immortalization and transformation functions., Virus Res. 2002 Nov;89(2):213-228.
24.Giarrè M, Caldeira S, Malanchi I, Ciccolini F, Leão MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol. 2001 May;75(10):4705-4712.
25.Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001 Jul;25(7):884-891.
26.Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med J. 2002 Dec;43(6):722-728.
27.Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, Howley PM. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4.
28.Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001 Mar 10;264(1):42-55.
29.Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol. 2003 Jul;16(7):665-73.
30.Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001 Apr 15;92(2):276-84.
31.Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002 Nov;26(11):1389-99.
32.Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, Shroyer KR. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol. 2004 Jun;35(6):689-696.
33.Schmitz MJ, Hendricks DT, Farley J, Taylor RR, Geradts J, Rose GS, Birrer MJ. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol. 2000 Jun;77(3):439-445.
34.McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003 Jul;22(3):231-235.
35.Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S. p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch. 2006 May;448(5):597-603.
36.Han CP, Lee MY, Tyan YS, Kok LF, Yao CC, Wang PH, Hsu JD, Tseng SW. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study. Virchows Arch. 2009 Oct;455(4):353-361.
37.Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004 Feb;28(2):160-167.
38.Khoury T, Tan D, Wang J, Intengan M, Yang J, Alrawi S, Yan P, Byrd JC. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol. 2006 Jan 12;6:1.
39.Wahlström T, Lindgren J, Korhonen M, Seppälä M. Distinction between endocervical and endometrial adenocarcinoma with immunoperoxidase staining of carcinoembryonic antigen in routine histological tissue specimens. Lancet. 1979 Dec 1;2(8153):1159-1160.
40.Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol. 1986 Aug;10(8):568-76.
41.Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002 Jan;21(1):4-10.
42.Dallenbach-Hellweg G, Schmidt D. Distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2002 Jul;21(3):307-308.
43.Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996 Feb;27(2):172-177.
44.Cohen C, Shulman G, Budgeon LR. Endocervical and endometrial adenocarcinoma: an immunoperoxidase and histochemical study. Am J Surg Pathol. 1982 Mar;6(2):151-157.
45.Maes G, Fleuren GJ, Bara J, Nap M. The distribution of mucins, carcinoembryonic antigen, and mucus-associated antigens in endocervical and endometrial adenocarcinomas. Int J Gynecol Pathol. 1988;7(2):112-122.
46.Masood S, Rhatigan RM, Wilkinson EW, Barwick KW, Wilson WJ. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. Cancer. 1993 Jul 15;72(2):511-518.
47.Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561-577.
48.Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978 Oct;8(4):283-298.
49.Centor RM. Signal detectability: the use of ROC curves and their analyses. Med Decis Making. 1991 Apr-Jun;11(2):102-106.
50.Gur D, King JL, Rockette HE, Britton CA, Thaete FL, Hoy RJ. Practical issues of experimental ROC analysis. Selection of controls. Invest Radiol. 1990 May;25(5):583-586.
51.Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993 Sep;189(8):862-866.
52.Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics (Sao Paulo). 2006 Oct;61(5):417-424.
53.Kamoi S, AlJuboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002 Jul;21(3):217-223.
54.Han CP, Lee MY, Tzeng SL, Yao CC, Wang PH, Cheng YW, Chen SL, Wu TS, Tyan YS, Kok LF. Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res. 2008 Aug 2;27:25.
55.Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002 Nov;8(11):1323-1327.
56.Hanley B. Variance in multiplex suspension array assays: carryover of microspheres between sample wells. J Negat Results Biomed. 2007 Apr 25;6:6.
57.Bodner G, Schocke MF, Rachbauer F, Seppi K, Peer S, Fierlinger A, Sununu T, Jaschke WR. Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. Radiology. 2002 May;223(2):410-416.
58.Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, Lee MY, Yang SF. Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol. 2009 Jun;22(6):797-806.
59.Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med. 2009 Apr 14;7:25.
60.Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 2009 Sep;280(3):405-413.
61.Han CP, Lee MY, Kok LF, Ruan A, Wu TS, Cheng YW, Tyan YS, Lin CY. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol. 2009 Sep;28(5):489-496.
62.Miller RT. Endocervical vs. endometrial adenocarcinoma. THE FOCUS – Immunohistochemistry 2002, 1-2.
63.McCluggage WG. A critical appraisal of the value of immunohistochemistry in diagnosis of uterine neoplasms. Adv Anat Pathol. 2004 May;11(3):162-171.
64.Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006 Aug;19(8):1091-1100.
65.Mhawech-Fauceglia P, Herrmann F, Bshara W, Zhang S, Penetrante R, Lele S, Odunsi K, Rodabaugh K. Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings. Int J Gynecol Pathol. 2008 Jul;27(3):431-436.
66.Wehling M. Translational medicine: science or wishful thinking? J Transl Med. 2008 Jun 17;6:31.
67.Yao CC, Kok LF, Lee MY, Wang PH, Wu TS, Tyan YS, Cheng YW, Kung MF, Han CP. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 2009 Sep;280(3):405-413.
68.Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, Koo CL, Wang PH, Chao KC, Han CP. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med. 2009 May 28;7:37.
69.Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch. 2010 Apr;456(4):377-386.
70.Xu MH, Deng CS, Zhu YQ, Lin J. Role of inducible nitric oxide synthase expression in aberrant crypt foci-adenoma-carcinoma sequence. World J Gastroenterol. 2003 Jun;9(6):1246-1250.
71.Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol. 1997 Jan;11(1):54-66.
72.Milde-Langosch K, Riethdorf L, Bamberger AM, Löning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch. 1999 Jan;434(1):23-28.
73.Fregonesi PA, Teresa DB, Duarte RA, Neto CB, de Oliveira MR, Soares CP. p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem. 2003 Oct;51(10):1291-1297.
74.Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005 Aug 10;23(23):5357-5364.
75.Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol. 2005 Nov;29(11):1497-1504.
76.Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995 May;10(1):114-116.
77.Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005 Jan;29(1):52-68.
78.Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995 Jan;103(1):41-47.
79.Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O''Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun;9(6):1941-1956.
80.Vallmanya Llena FR, Laborda Rodríguez A, Lloreta Trull J, Cortadellas Angel R, Placer Santos J, Mas Gelabert A. Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study. Actas Urol Esp. 2006 Sep;30(8):754-762.
81.Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, Lu D, Yu SC, Hsiung CY. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006 Dec;13(12):1633-1744.
82.Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F; AGO-OVAR. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer. 2007 Jan 29;96(2):306-313.
83.Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008 Mar;132(3):402-423.
84.Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001 May;67(1):61-70.
85.McCluggage WG. Re: Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection. Am J Surg Pathol. 2004 Jul;28(7):974.